Lucia Rajcic

All articles by Lucia Rajcic

• Study highlights the clinical benefits of PEG-IFN-α in SM

  New real-world data reports on the efficacy of pegylated interferon-α for treating systemic mastocytosis and other hematologic neoplasms.

• Drug-induced anaphylaxis can be the first sign of SM

  A recent study evaluates the link between medication allergies and systemic mastocytosis, focusing on high-risk drugs like NSAIDs.

• Gastrointestinal mastocytosis carries risks even when symptoms are missing

  Even without symptoms, gastrointestinal mastocytosis carries a risk of bone marrow involvement, according to new research.

• New study suggests CD123 could be a therapeutic target in SM

  Researchers found CD123 expression in 91% of SM cases, showing it is a frequent and stable marker in nearly all disease subtypes.

• Study suggests sFcεRI may play a dual role in SM severity and protection

  A new study reveals that sFcεRI acts as a biomarker of systemic mastocytosis severity while potentially protecting against anaphylaxis.